glp-1/gip/glucagon triple agonist name Main physiological actions of the dual GIP and GLP-1 Dual and Triple Gut Peptide
Description
With Saxenda, people can lose about 5-10% of their body weight
In other CVOTs most patients received target dose (maximal tolerated dose) and no analysis was done regarding dose-dependent effects
J Diabet Invest 7(suppl 1):812
GLP-1 utilization isn't slowing downand employers are feeling the impact
If you feel you may benefit from a medication such as CONTRAVE, please discuss a treatment plan with your doctor
